Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05990491
Other study ID # A-05-PGI/IMP/87/2023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 28, 2023
Est. completion date August 2025

Study information

Verified date August 2023
Source Sanjay Gandhi Postgraduate Institute of Medical Sciences
Contact Harilal K, MD
Phone +91-8089728532
Email hari2012686@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prolonged circulatory shock is associated with marked disturbances in vascular supply to the brain, and endothelial dysfunction which can lead to disseminated intravascular coagulation and microvascular thrombosis. Pituitary dysfunction is documented following post-partum hemorrhage, traumatic brain injury and subarachnoid hemorrhage, which also affect blood flow to the pituitary. However, there are no studies assessing pituitary function in the aftermath of recovery from shock. This will be a prospective observational study of patients admitted in Critical Care Medicine (CCM) ICU who have recovered from prolonged septic shock (Lasting for a period of > 24 hours). Blood samples of the participants will be estimated at the time of discharge from the ICU and at 6 months post discharge. Investigators will estimate fasting serum cortisol, TSH, Free T4, Testosterone (in males), Oestrogen (in females), LH, FSH, Prolactin, IGF-1 and plasma ACTH in all participants at both time points (at the time of ICU discharge and at 6-months follow-up). Participants who have borderline serum cortisol values (138-400 nmol/l) will be subjected to 250ug ACTH stimulation test. Expected outcome of the proposed study is to know proportion of patients having pituitary hormone axis dysfunction. Investigators will also look for pituitary dysfunction persist or revert, or there are new onset dysfunction at 6 month follow up. This would have major implications in the follow up and management of ICU survivors.


Description:

The pituitary gland receives its arterial blood supply from the superior and inferior hypophyseal arteries, which arise from the internal carotid artery. The infundibulum, the median eminence and the pars tuberalis are supplied by the superior hypophyseal artery and the posterior lobe by the inferior hypophyseal artery. By contrast, the pars distalis (anterior pituitary) is mainly supplied by the venous system. The long portal system, arising from the capillary plexus around the median eminence, and the short portal system arising from the posterior pituitary account for 70% and 30% respectively, of the total blood supply to the anterior pituitary gland. This unique circulation allows the pars distalis to receive humoral signals from the hypothalamus and the posterior pituitary; however, it renders the pituitary susceptible to ischemia due to hypotension, hypovolemia and vascular thrombosis. The prototype illness where pituitary necrosis leads to pituitary dysfunction is post-partum pituitary necrosis (Sheehan syndrome). The pituitary gland becomes vulnerable to changes in blood flow during and shortly after pregnancy owing to the increased size of the gland, leading to both increased demand and compression of the vasculature of the gland. In addition, pregnancy is a thrombophilic state which increases risk for intravascular thrombosis. Hypotension secondary to post-partum hemorrhage causes pituitary necrosis and leads to hypopituitarism. Vascular insults to the pituitary are also implicated in other forms of pituitary damage, such as following traumatic brain injury, following snakebite envenomation, subarachnoid hemorrhage and hemorrhagic shock. Circulatory shock replicates many of the pathophysiological processes described above. Clinical classifications of shock include hypovolemic, cardiogenic, distributive (septic), and obstructive types. While the pathophysiology of each type of shock is different and complex, the final common pathway is poor perfusion, anaerobic metabolism, lactic acidosis, and release of inflammatory mediators with resultant tissue damage. Sepsis and septic shock are often complicated by Disseminated Intravascular Coagulation (DIC) which leads to widespread microvascular thrombosis. Hypotension leads to reduced blood flow to the hypothalamo-pituitary unit and all these factors may lead on to ischemia and infarction of the hypothalamo-pituitary unit. Patients who recovered post cardiac arrest suffer an extreme form of this insult where blood flow to the brain is almost entirely cut off for a period of time, followed by reperfusion. Post ICU Care Syndrome (PICS) is estimated to occur in 30-80% of patients post discharge from the intensive care unit. Many of the manifestations of Post ICU Care Syndrome (PICS), such as fatigue, cognitive dysfunction, neuromuscular weakness, amenorrhea and sexual dysfunction overlap with those seen in hypopituitarism. However, there is no literature describing the role of pituitary dysfunction in these patients. Based on the above evidence, we hypothesize that patients who recover from severe shock may have hypothalamic-pituitary damage leading to hypopituitarism. Due to the current lack of literature on this topic, we propose to study pituitary function in ICU survivors who recovered from the septic shock. The primary objective is to study the prevalence of dysfunction of various pituitary hormone axes at the time of ICU discharge in participants who recovered from the septic shock. The secondary objective is to look for the recovery of pituitary function or new onset pituitary dysfunction at 6 months post-discharge from the ICU, in these included participants. This will be a prospective, observational study of participants undergoing treatment for septic shock in the Department of Critical Care Medicine (CCM), SGPGIMS, Lucknow. Details of premorbid conditions, precipitating illness, clinical parameters and treatments provided to the participants will be recorded. Levels of pituitary hormones [Cortisol (Basal and stimulated), ACTH, IGF-1, LH, FSH, Testosterone (in males), Estradiol (in females), Prolactin, TSH and free T4] will be assessed in fasting state, prior to discharge from the ICU. Participants will be interviewed telephonically at 3 months post-discharge to assess quality of life using the SF-36 questionnaire and for symptoms suggestive of hypopituitarism. At 6 months post-discharge, the various pituitary hormone levels [Cortisol (Basal and stimulated), ACTH, IGF-1, LH, FSH, Testosterone (in males), Estradiol (in females), Prolactin, TSH and free T4] will be assessed again along with assessment of quality of life using SF-36. Any pituitary hormone deficiency identified on testing will be evaluated and managed as per standard practice. Investigators aim to include 90 participants in the study. Continuous variables will be presented in mean and standard deviation (SD) or median (interquartile range) depending upon normality status. Independent samples t test (for independent groups) / Paired t test (paired groups) or their non-parametric counterparts will be used to compare the means or medians between the groups, respectively. Categorical variables will be presented in number (%) and will be compared by Chi square test / Fisher exact test, as appropriate. One-way Repeated Measures ANOVA or Friedman test will be used to compare the means or medians over the time as appropriate. Binary logistic regression analysis will be used to assess the factors associated with pituitary dysfunction among the study participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date August 2025
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients 18-80 years of age who meet the definition of septic shock. - Vasopressor requirement should be maintained for a period > 24 hours and should require ICU stay for a duration of > 7 days. - Patient should recover from shock and be planned for discharge from the ICU. Exclusion Criteria: - Patients who refuse to provide consent. - Age <18 years or > 80 years of age. - Pregnancy or immediate post-partum (< 6 months post-delivery). - Chronic kidney disease (Stage 5), chronic liver disease (CHILD B or C), severe Chronic obstructive pulmonary disease, Chronic heart failure. - Patients with pre-existing hypopituitarism on replacement. - Past history of severe post-partum hemorrhage requiring blood transfusion, traumatic brain injury, subarachnoid hemorrhage, pituitary tumor/surgery, snake bite envenomation and meningo-encephalitis. - Patients who have been on > 5 mg prednisolone equivalent for a period of more than 2 weeks at any time in the previous 6 months before admission.

Study Design


Locations

Country Name City State
India Department of Critical Care Medicine, SGPGIMS Lucknow UP
India Department of Endocrinology, SGPGIMS Lucknow Uttar Pradesh

Sponsors (1)

Lead Sponsor Collaborator
Sanjay Gandhi Postgraduate Institute of Medical Sciences

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pituitary dysfunction at discharge Frequency of dysfunction of various hypothalamo-pituitary hormone axes Immediately before the ICU discharge
Secondary Pituitary dysfunction at 6 months Frequency of dysfunction of various hypothalamo-pituitary hormone axes on follow up Six months after the ICU discharge
See also
  Status Clinical Trial Phase
Recruiting NCT03592693 - Vitamin C, Hydrocortisone and Thiamine for Septic Shock Phase 2
Terminated NCT01639664 - COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2 N/A
Withdrawn NCT01601938 - Selenium Replacement and Serum Selenium Level in Severe Sepsis and Septic Shock Patients Phase 2
Recruiting NCT00335907 - Protocol-driven Hemodynamic Support for Patients With Septic Shock N/A
Completed NCT00000574 - Ibuprofen in Sepsis Study Phase 3
Recruiting NCT04910841 - Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine N/A
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Recruiting NCT04569942 - Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Phase 3
Recruiting NCT04934943 - "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"
Completed NCT01310790 - Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis and Septic Shock Phase 4
Completed NCT00241228 - Haemofiltration Study : IVOIRE (hIgh VOlume in Intensive Care) N/A
Completed NCT00046072 - A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis Phase 2
Withdrawn NCT03122678 - Thiamine Supplementation in Patients With Septic Shock Phase 1
Recruiting NCT06155812 - Multimodal Vasopressor Strategy in Septic Shock Phase 2/Phase 3
Completed NCT04178148 - Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock N/A
Completed NCT01453270 - Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial N/A
Completed NCT04576819 - Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis
Active, not recruiting NCT04055909 - Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock Phase 2
Suspended NCT03193164 - Neuromuscular Electrical Stimulation and Septic Shock N/A
Completed NCT04647552 - Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock